Plex Pharmaceuticals

Plex Pharmaceuticals, Inc. (formerly CalAsia Pharmaceuticals) is an early-stage biotechnology company with drug discovery expertise focused on diseases caused by protein misfolding: ALS, Parkinson's disease, and cataracts. Plex Pharmaceuticals also has a development program for antiviral drugs targeting dengue, West Nile, and Zika, which is supported by the National Institutes of Health, and is committed to developing a novel brain-penetrant heat shock protein 90 (HSP90) inhibitor for the treatment of glioblastoma.